Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian C Shaffer

Showing results (61-70 of 79) with videos related to

Pageof 8
Sort By:
Bone Marrow Transplantation|July 23, 2020
Geriatric syndromes in 2-year, progression-free survivors among older recipients of allogeneic hematopoietic cell transplantationRichard J Lin, Raymond E Baser, Theresa A Elko, et al.
Blood Advances|December 8, 2020
High progression-free survival after intermediate intensity double unit cord blood transplantation in adultsJuliet N Barker, Sean M Devlin, Kristine A Naputo, et al.
JAMA Network Open|May 5, 2026
Hematopoietic Cell Transplant Access and Patient DiversityRachel Cusatis, Jianqun Kou, Caitrin Bupp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2025
Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell TransplantationMonzr M Al Malki, Stephanie Bo-Subait, Brent Logan, et al.
Transplantation and Cellular Therapy|December 30, 2022
Three-Year Outcomes in Recipients of Mismatched Unrelated Bone Marrow Donor Transplants Using Post-Transplantation Cyclophosphamide: Follow-Up from a National Marrow Donor Program-Sponsored Prospective Clinical TrialBronwen E Shaw, Antonio Martin Jimenez-Jimenez, Linda J Burns, et al.
Journal of Palliative Medicine|March 29, 2020
Characteristics and Impact of Post-Transplant Interdisciplinary Palliative Care Consultation in Older Allogeneic Hematopoietic Cell Transplant RecipientsRichard J Lin, Abigail G Cohen, Stacy M Stabler, et al.
Leukemia & Lymphoma|September 3, 2021
Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplantJan Philipp Bewersdorf, Andriy Derkach, Lohith Gowda, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2021
National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant CyclophosphamideBronwen E Shaw, Antonio Martin Jimenez-Jimenez, Linda J Burns, et al.
Blood Advances|June 12, 2025
Bone marrow and blood demonstrate distinct immune reconstitution patterns and correlations with relapse post-transplantSusan DeWolf, Jason Kuttiyara, Paola Vinci, et al.
Transplantation and Cellular Therapy|March 17, 2021
Cellular Therapy During COVID-19: Lessons Learned and Preparing for Subsequent WavesMariam T Nawas, Gunjan L Shah, Darren R Feldman, et al.
Pageof 8

Showing results (61-70 of 79) with videos related to

Sort By:
Pageof 8
Bone Marrow Transplantation|July 23, 2020
Geriatric syndromes in 2-year, progression-free survivors among older recipients of allogeneic hematopoietic cell transplantationRichard J Lin, Raymond E Baser, Theresa A Elko, et al.
Blood Advances|December 8, 2020
High progression-free survival after intermediate intensity double unit cord blood transplantation in adultsJuliet N Barker, Sean M Devlin, Kristine A Naputo, et al.
JAMA Network Open|May 5, 2026
Hematopoietic Cell Transplant Access and Patient DiversityRachel Cusatis, Jianqun Kou, Caitrin Bupp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2025
Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell TransplantationMonzr M Al Malki, Stephanie Bo-Subait, Brent Logan, et al.
Transplantation and Cellular Therapy|December 30, 2022
Three-Year Outcomes in Recipients of Mismatched Unrelated Bone Marrow Donor Transplants Using Post-Transplantation Cyclophosphamide: Follow-Up from a National Marrow Donor Program-Sponsored Prospective Clinical TrialBronwen E Shaw, Antonio Martin Jimenez-Jimenez, Linda J Burns, et al.
Journal of Palliative Medicine|March 29, 2020
Characteristics and Impact of Post-Transplant Interdisciplinary Palliative Care Consultation in Older Allogeneic Hematopoietic Cell Transplant RecipientsRichard J Lin, Abigail G Cohen, Stacy M Stabler, et al.
Leukemia & Lymphoma|September 3, 2021
Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplantJan Philipp Bewersdorf, Andriy Derkach, Lohith Gowda, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2021
National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant CyclophosphamideBronwen E Shaw, Antonio Martin Jimenez-Jimenez, Linda J Burns, et al.
Blood Advances|June 12, 2025
Bone marrow and blood demonstrate distinct immune reconstitution patterns and correlations with relapse post-transplantSusan DeWolf, Jason Kuttiyara, Paola Vinci, et al.
Transplantation and Cellular Therapy|March 17, 2021
Cellular Therapy During COVID-19: Lessons Learned and Preparing for Subsequent WavesMariam T Nawas, Gunjan L Shah, Darren R Feldman, et al.
Pageof 8